cyrilzakka/clinical-trials huggingface dataset:
Impact of Peripheral Nerve Blockade on Outcomes After Total Knee Replacement

Pain is common after knee replacement surgery and can impact a variety of patient outcomes. Peripheral nerve blocks provide improved pain control and may improve function. However, their impact on other outcomes is poorly described. Therefore, this comparative effectiveness study will estimate the independent association between nerve blocks and health outcomes after knee replacement surgery.

This retrospective, population-based cohort study will evaluate the comparative effectiveness of peripheral nerve blocks on patient and health system outcomes after elective total knee replacement surgery.

The investigators will develop a non-parsimonious propensity score to control for potential indication bias and confounding in this observational study. Using the propensity score the investigators will match patients who receive a peripheral nerve block to a patient who did not to estimate the independent association of peripheral nerve blocks with our study outcomes.

Eligibility Criteria:
Inclusion Criteria:

* first primary total knee replacement during the study period

Exclusion Criteria:

* Revision arthroplasty
The Effect of Food Labelling and Satiety on Individuals Food Choice

Previous research has shown that nutritional knowledge is a key indicator in healthy eating choices, but real-life examinations of the associations between both nutritional knowledge and state of hunger and satiety on individuals' food choice of healthy vs unhealthy snacks is limited.

The present study aims to investigate whether the presence of nutritional information on food labels will affect participants' food choice when hungry and when satiated.

Previous research has shown that nutritional knowledge is a key indicator in healthy eating choices, but real-life examinations of the associations between both nutritional knowledge and state of hunger and satiety on individuals' food choice of healthy vs unhealthy snacks is limited.

As there is currently little research combining these facets, it would be interesting to investigate whether individuals who are provided with food labelling information would choose unhealthy snacks when hungry as than when satiated and whether this would differ for those who are not provided with food labelling information.

Based on this, the present study aims to investigate whether the presence of nutritional information in the form of food labels will affect participants' food choice when hungry and when satiated. The General Nutrition Knowledge Questionnaire will be used to assess participants baseline nutritional knowledge and will be used as a covariate in the research project.

Eligibility Criteria:
Inclusion Criteria: Male and females aged 18-65 years old; in general good health; not known allergies and any medical conditions (e.g. heart disease, asthma)

Exclusion Criteria: Those who are currently following a weight loss diet; have food allergies and any medical conditions which might restrict their food intake
Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?

The purpose of this study is to investigate within a short delay the effect of nasal instillation of Miglustat on nasal potential difference in cystic fibrosis patients homozygous for the F508del mutation.

Miglustat is an inhibitor of α-glucosidases and other enzymes. Oral miglustat is currently marketed in Europa and US for the treatment of Gaucher type 1 patients for whom enzyme replacement treatment is not an option.

Gastro-intestinal side effects are common with this formulation. This medication has been shown to have a beneficial effect both on Cl- an Na+ transports in cystic fibrosis epithelial cells. In addition, a single airway delivery of low-dose Miglustat normalizes nasal potential difference (NPD) in F508del cystic fibrosis mice. NPD abnormalities specific of CF patients are considered to reflect the primary defect of CFTR protein so that any curative treatment is expected to correct them at least partially.

In the field of respiratory pharmacology, it is a general rule that the inhaled route is to be favoured whenever possible : it is usually more effective despite much lower doses and systemic absorption (which also implies lower costs and improved tolerance).

The aim of this study is to investigate the effect of a single local administration of Miglustat on NPD measurements in CF patients homozygous for the F508del mutation.

Eligibility Criteria:
Inclusion Criteria:

* Cystic fibrosis patients homozygous for the F508del mutation as confirmed by genetic test
* Aged 14 years and older
* Male or female (non-pregnant women who are to remain non-pregnant for 3 months after the end of the study)
* FEV1 \> 50% of predicted normal

Exclusion Criteria:

* Acute respiratory tract infection or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of visit 1
* Any condition prohibiting the correct measurement of the NPD such as respiratory tract infection
* Active or passive smoking
* Allergic chronic rhinitis
* History of significant lactose intolerance
* History of neuropathy
* History of cataracts or known increased risk of cataract formation
* Hypersensitivity to miglustat or any excipients
* Planned treatment or treatment with another investigational drug or therapy within 1 month prior to randomisation
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice


Eligibility Criteria:
Inclusion Criteria:

* Patients of both gender older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
* Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion

Exclusion Criteria:

* Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler
Exercise Effects on Cardiovascular Risk Factors, Quality of Life, Muscle Function in Type 2 Diabetes and Healthy Persons

A sedentary lifestyle is known to be a risk factor to developing type 2 diabetes. The aim of this study was to determine the effects of adding regular Nordic walking to daily physical activity. Effects on quality of life, cardiovascular risk factors and functions in muscle cells will be determined.

Regular physical activity is known to have a beneficial effect on several factors affecting the risk of developing cardiovascular disease and type 2 diabetes. Implementing and maintaining changes of lifestyle is, however, known to be difficult. In this study we wished to investigate the effects of an exercise intervention that is feasible to most people with type 2 diabetes or at risk of developing that disease. The intervention was Nordic walking (with walking poles) for five hour per week, during four months. We chose to determine effects on health related quality of life, clinical parameters related to body weight/body composition, blood pressure, glucose metabolism, insulin resistance, blood lipids, oxygen uptake and physiological effects in skeletal muscle cells related to glucose metabolism.

On inclusion and after four months the participants were therefore subject to clinical measurements, blood samples, maximal oxygen uptake tests on an ergometer cycle and muscle biopsies at inclusion and after four months of participation. They also answered an extensive questionnaire focusing on health related quality of life.

Eligibility Criteria:
Inclusion Criteria:

* BMI\>25

Exclusion Criteria:

* Physical impairment
* Symptomatic angina pectoris
* Insulin treatment
Splint Versus Non-splint Implant Impressions

The purpose of this study is to evaluate the effectiveness of heavy Vinyl PolySiloxane (VPS) and splinted implants impression (Study Group, SG) technique versus plaster implant impression (Control Group, CG) technique, in 12 edentulous patients rehabilitated with the All-on-4/6 concept and Procera® Implant Bridge (P.I.B.). A longitudinal, double blinded, randomised clinical trial (RCT) was designed to evaluate the accuracy of the impression. All patients were monitored from implant placement until prosthetic loading.

The aim of the present study was to investigate the accuracy of pick-up, splinted implants, and heavy VPS impression techniques (Aquasil Putty DECA™ and Aquasil Ultra Light Viscosity (LV) Regular Set, Dentsply International Inc, Caulk, USA); to compare two splint materials for implants: Primopattern LC gel (Primotec, Bad Homburg, Germany), and Smart Dentin Replacement (SDR™, Dentsply International Inc, Caulk, USA); to examine the clinical factors affecting the accuracy of implant impressions; to test the tension-free fit of the new scanner and software NobelProcera™ (NobelBiocare, AB, Göteborg, Sweden) titanium frameworks.The hypothesis to demonstrate is that all impression techniques and used materials reduce time for final restoration and improve the accuracy of the impression.

Eligibility Criteria:
Inclusion Criteria:

* Age 21 years or older.
* Both genders.
* Fully edentulous patients.
* Both maxilla and mandible.
* Dental implant rehabilitation utilizing the All-on-4 concept at least 8 weeks before impression.
* External hex dental implant.
* Patients with ability to understand and sign the informed consent prior to starting the study.
* Adequate oral hygiene.
* Immediate functional loading.
* Implant stability quote value =/\> 65 from implant placement to final prosthetic rehabilitation.

Exclusion Criteria:

* Failure of one or more inclusion criteria.
Bascom Cleft Lift Versus Limberg Flap for Sacrococcygeal Pilonidal Sinus

A pilonidal sinus is a cyst on the natal cleft of the buttocks that often contains hair and skin debris. The condition is common and requires surgery to be cured. Several surgical procedures are described in literature. Limberg Flap technique is frequently used technique for this disease all over the world. However, Bascom Cleft Lift Technique is relatively newer technique. The purpose of this prospective randomized study is comparison of these techniques about patient satisfaction for postoperative period.


Eligibility Criteria:
Inclusion Criteria:

* All types of pilonidal sinus or cyst
* The patient understands trial information and is capable of making a decision for informed consent after having received information.
* The patient wants to undergo surgery for pilonidal sinus and accepts participation in the trial.

Exclusion Criteria:

* acute abscess formation (Cruse-Foord Class IV)
* patient with minor inflammation are included to trial after two-week antibiotic treatment (Cruse-Foord Class III)
At-Home Neuromodulation for Female Sexual Dysfunction

This pilot study investigates the regular use of non-invasive dorsal genital nerve stimulation (DGS) for the treatment of female sexual dysfunction (FSD). The researchers aim to determine whether subjects with FSD can correctly follow an at-home treatment regimen and to demonstrate that DGS can improve FSD arousal symptoms in premenopausal and postmenopausal women.


Eligibility Criteria:
Inclusion Criteria:

* Capable of speaking and understanding English.
* Able to comprehend the clinical study procedures and provide informed consent.
* Identified as having female sexual dysfunction with a Female Sexual Function Index (FSFI) score of 26.55 or less and a score of 3 or less on one or more of the FSFI subdomains of lubrication, arousal, and orgasm.
* Willing and able to adhere to the study protocol
* Able to attend experimental sessions at Michigan Medicine at both the start and conclusion of the study.

Exclusion Criteria:

* Not currently sexually active.
* Pregnant or planning to get pregnant during the study period.
* History of a neurological disorder or impairments affecting pelvic organ function, including diagnosed with dorsal genital nerve damage, lower motor dysfunction, or other related conditions.
* Implanted with a neurostimulator for bladder or bowel function.
* Have a skin condition that would predispose them to sensitivity to the stimulation electrodes.
* Female sexual dysfunction limited solely to low desire, without issues in lubrication, arousal, or orgasm.
* Clinically diagnosed bladder dysfunction, pelvic pain, or other pelvic organ symptoms; or a score of 8 or higher on the American Urological Association Symptom Index (AUASI).
* Unable or unwilling to adhere to the study protocol
* Simultaneously participating in another research study that may affect the results of this study.
Aromatherapy Inhalation in Psychiatric Nurses

In this study will be conducted with a total of 66 psychiatric nurses who meet the inclusion and exclusion criteria and are working at Ankara Etlik City Hospital Psychiatry Clinic between January 1, 2025 and March 31, 2025.

In this study, aromatherapy inhalation will be applied to psychiatric nurses in the experimental group. Aromatherapy inhalation using 2% diluted lavender essential oil will be applied to 33 psychiatric nurses in the experimental group, 30 minutes before starting work, every other day during a week. The "General Job Stress Scale (GJSS)" and "Therapeutic Relationship Evaluation Scale-Nurse Form (TRES-NF)" inventories will be filled out by 33 psychiatric nurses in the experimental group before and after aromatherapy inhalation, and by 33 psychiatric nurses in the control group simultaneously with the psychiatric nurses in the experimental group.

Eligibility Criteria:
Inclusion Criteria:

* Written permission was obtained before participating in the study
* Having worked in the psychiatry departments of the relevant institution for at least 1 year
* Working in the psychiatry departments of the relevant institution during the study dates
* Not sensitive to the odor of lavender essential oil

Exclusion Criteria:

* Previous experience with aromatherapy
* Sensitivity and allergy to lavender essential oil
* Willingly leaving the study while the study was ongoing
* Leaving the job during the study period
* General condition changes during the study period (developing allergies, getting sick, taking annual leave, taking leave with a health report)
* Becoming a service responsible nurse
Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant

Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to prevent transplant rejection, are based on chemotherapy alone or combined with total body irradiation (TBI). Endocrine complications are frequent transplant-related side effects. Investigators have been well described in children studies but less in adulthood.

The objective of this study is to assess retrospectively endocrine, bone and metabolic disorders in adult patients, 12 months after allo-HSCT.

Patients \& Methods Inclusion criteria are : patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease; adult and in complete remission at exploration.

Exclusion criteria are : anteriority of brain radiotherapy and prior HSCT.

Twelve months after HSCT, each patient underwent fasting measurement of IGF1, TSH, fT4, FSH, LH, sex steroids, glycemia, insulin level, and lipid profile. Unless contraindication, adrenal and growth hormone functions were assessed with insulin hypoglycemia test. A dual X-ray absorptiometry was also performed.

Investigators will assess the prevalence of endocrine, bone and metabolic disorders 12 months after allo-HSCT and describe some of their risk factors.

Eligibility Criteria:
Inclusion Criteria:

* patients treated with allo-HSCT from 2006 to 2016 for a malignant hematologic disease
* adult and in complete remission at exploration.

Exclusion Criteria:

* anteriority of brain radiotherapy
* prior HSCT
* pregnancy
Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents

The goal of a pilot study is to test a study plan to see if it is appropriate for a larger study. This study plan is looking at whether the use of inhaled sedatives (medications that help people be calm and sleep) can reduce delirium (extreme confusion) in children who need a ventilator (breathing machine) compared to IV or oral sedatives.

The main question\[s\] it aims to answer are:

* Will people join the study? (recruitment)
* Will participants finish the study?
* Will healthcare teams accept the study procedures?

Participants will be randomized to receive study treatment (inhaled sedation) or standard of care (IV sedation). They will be monitored daily for up to 28 days. They will complete memory, thinking and behaviour tasks after 9-12 months.


Eligibility Criteria:
Inclusion Criteria:

1. Pediatric patients age from 1 month to less than 18 years who need sedation to tolerate mechanical ventilation and will remain ventilated for ≥ 24 hours.
2. Receiving IV sedation by infusion or bolus for ≤72h to aid mechanical ventilation (but will be recruited as early as possible).

Exclusion Criteria:

1. Current use of inhaled prostacyclin (high viscosity of prostacyclin impairs vaporizer device)
2. Family history or personal history of malignant hyperthermia (MH)
3. Allergy to isoflurane, sevoflurane or other volatile inhaled anesthetic gas
4. Metabolic, mitochondrial or myopathy disease e.g., Duchenne muscular dystrophy (volatiles may trigger malignant hyperthermia like reaction)
5. Moribund with expected survival \< 24h
6. Known pregnancy or lactation
7. Suspected or evidence of high intracranial pressure (ICP)
Comparison of Serum Calcium Level Between Preoperative Vitamin D and Non-vitamin D Regimen of Total Parathyroidectomy in End-stage Renal Failure Patients in Rajavithi Hospital

This Research is compare about IV Calcium between end-stage renal failure patients who take vitamin D and non-vitamin D preoperative parathyroidectomy


Eligibility Criteria:
Inclusion Criteria:

* New End-stage renal failure patients and have iPTH\>800 pg/dl at least 6 months
* Patients who no response hyperphosphatemia with high dose vitamin D

Exclusion Criteria:

* Allergy vitamin D
* Pregnancy
* Patients who parathyroidectomy have less than 4 gland
Stimulation of the Rostral Zona Incerta for Parkinson's Disease

Patients with Parkinson's Disease who undergo Deep Brain Stimulation surgery receive symptom relief due to electrical stimulation of the brain. The target for the stimulation, in many cases, is the subthalamic nucleus (STN). The brain area just above the STN is called the rostral Zona Incerta (rZI). The rZI may be a potential target for deep brain stimulation, in combination with the STN.

Deep brain stimulation (DBS) of an area of the brain called the subthalamic nucleus (STN) is an effective treatment in Parkinson's disease (PD). However, stimulating the STN can lead to unwanted side effects that involve muscle movements (dyskinesias) and behavior and mood problems. DBS of a different brain structure, called the rostral zona incerta (rZI), has been demonstrated to be as effective as stimulating the STN, without any unwanted side effects in several studies. However, there is great variability in reported efficacy and adverse effects of rZI stimulation likely due to challenges in locating this area in the brain. The goals of this study are 1) to develop an improved method for targeting the rZI 2) determine efficacy of rZI with STN stimulation compared with STN stimulation alone, 3) evaluate any stimulation adverse effects of combined stimulation of the rZI and STN.

Eligibility Criteria:
Inclusion Criteria:

* Parkinson's Disease,
* No current deep brain stimulating electrodes

Exclusion Criteria:

* Other movement disorders,
* Parkinson's Disease with already implanted electrode.
The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement

Patients experience pain after their knee replacement surgery - and some may continue to experience persistent pain long after their knee replacement surgery. Traditional pain management strategies reply on pain medication such as opioids for pain control. However, these drugs do not work well for pain associated with movement or the the nerve pain (tingling, electrical sensations) after surgery. In addition, opioids are associated with significant side effects such as nausea, vomiting, respiratory depression, depression, cognitive dysfunction and risk of persistent opioid use. Neuropathic pain medications, such as venlafaxine are effective in managing nerve pain. Recent studies also support its potential role in acute pain management. Here, we propose a prospective randomized clinical trial 1) to evaluate the efficacy of Venlafaxine in reducing pain intensity and opioid consumption at post-operative day 1 (POD1) and 1- week after surgery, and 2) to examine whether the use of Venlafaxine will reduce the incidents of chronic postsurgical pain in TKA patients at 3-month time point.

Patients meeting the inclusion criteria will be randomized to receive either Venlafaxine extended release (ER) 37.5 mg/d or a placebo on the day of surgery and continue the treatment for 7 days after surgery. The primary outcomes include pain severity score (numeric rating scale, NRS) and consumption of morphine miligram equivalent (MME) at 24 hours. The secondary outcome will measure MME and NRS at postoperative day 7. In addition, the disability scale and perceived function 3 months after surgery will be compared to the baseline level by using PROMIS (Patient-Reported Outcomes Measurement Information System)10 Global Health, KOOS, JR. (Knee injury and Osteoarthritis Outcome Score Short Form), and VR-12 (Veterans RAND 12 Item Health Survey) Scale.

Eligibility Criteria:
Inclusion Criteria:

* adult (male and female) subjects aged 18 to 75,
* English speaking,
* are scheduled for primary total knee arthroplasty with planned spinal anesthesia with saphenous peripheral nerve block at the adductor canal.

Exclusion Criteria:

* general anesthesia,
* hepatic \& renal failure,
* history of diabetic peripheral neuropathic pain,
* chronic opioid use,
* concurrent use of antidepressants, triptans, and/or linezolid,
* allergy to the study medications,
* prior knee surgery,
* BMI \> 40,
* bleeding disorders,
* history of recent falls,
* concurrent benzodiazepine use.